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Abstract
Access to lifelong combination antiretroviral therapy (cART) is expanding among HIV-infected 
pregnant and breastfeeding women throughout sub-Saharan Africa. For this strategy to 
meaningfully improve maternal HIV outcomes, retention in HIV care is essential. We developed a 
risk score to identify women with high likelihood of loss to follow-up (LTFU) at 6 months 
postpartum from HIV care, using data from public health facilities in Lusaka, Zambia. LTFU was 
defined as not presenting for HIV care within 60 days of the last scheduled appointment. We used 
logistic regression to assess demographic, obstetric, and HIV predictors of LTFU and to develop a 
simple risk score. Sensitivity and specificity were assessed at each risk score cut-point. Among 
2,029 pregnant women initiating cART between 2009 and 2011, 507 (25%) were LTFU by 6 
months postpartum. Parity, education, employment status, WHO clinical stage, duration of cART 
during pregnancy, and number of antenatal care visits were associated with LTFU (p-value<0.10). 
A risk score cut-point of 11 (42nd percentile) had 85% sensitivity (95% CI 82%, 88%) and 22% 
specificity (95% CI 20%, 24%) to detect women LTFU and would exclude 20% of women from a 
retention intervention. A risk score cut-point of 18 (69th percentile) identified the 23% of women 
with the highest probability of LTFU and had sensitivity 32% (95% CI 28%, 36%) and specificity 
80% (95% CI 78%, 82%). A risk score approach may be useful to triage a subset of women most 
likely to be LTFU for targeted retention interventions.
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INTRODUCTION
Access to lifelong combination antiretroviral therapy (cART) is rapidly being scaled-up to 
HIV-infected pregnant and breastfeeding women throughout sub-Saharan Africa (SSA). In 
2013, an estimated 68% of HIV-infected pregnant women received some type of 
antiretroviral drug during pregnancy and delivery, doubled from 33% in 2009 (UNAIDS, 
2014). In countries with a generalized HIV epidemic, the World Health Organization 
(WHO) now recommends lifelong cART for all pregnant and breastfeeding women (Kieffer 
et al., 2014; WHO, 2013). This strategy, known as Option B+(Schouten et al., 2011), has 
become the standard of care in many SSA countries. Option B+ is recognized as a critical 
component for preventing mother-to-child transmission of HIV (PMTCT), improving 
maternal health, and reducing the risk of sexual transmission among serodiscordant couples 
(Ahmed, Kim, & Abrams, 2013).
For Option B+ to improve HIV outcomes, women must remain in HIV care and maintain 
viral suppression (Hirnschall, Harries, Easterbrook, Doherty, & Ball, 2013; Rosen & Fox, 
2011; Thompson et al., 2012). Unfortunately, loss to follow-up (LTFU) during and after 
pregnancy is common (Shaffer, Abrams, & Becquet, 2014). In Malawi, 17% of women 
initiating cART during pregnancy were LTFU by 6 months after treatment initiation. 
Retention at 12 months was lower among pregnant women than among other adults 
initiating cART (Kieffer et al., 2014; Tenthani et al., 2014). In South Africa, 32% of women 
initiating cART during pregnancy were lost by 6 months postpartum (Phillips et al., 2014). 
Several factors have been associated with LTFU among pregnant women, including younger 
age (Boyles, Wilkinson, Leisegang, & Maartens, 2011), initiating treatment at higher CD4 
counts (Tenthani et al., 2014), timing of presentation to antenatal care (ANC) (Panditrao, 
Darak, Kulkarni, Kulkarni, & Parchure, 2011; Westreich, Evans, Firnhaber, Majuba, & 
Maskew, 2012) and receiving a new HIV diagnosis during pregnancy (Kaplan, Orrell, 
Zwane, Bekker, & Wood, 2008). To date, strategies to identify women at time of delivery 
who are at high risk of LTFU are lacking.
To address this gap, we developed a risk score to identify women LTFU from HIV care by 6 
months postpartum using data from public health facilities in Lusaka, Zambia. 
Demographic, obstetric, HIV predictors were used to develop a simple, user-friendly scoring 
system that could be implemented by clinicians at delivery to identify women at highest risk 
of LTFU for retention interventions. Since Zambia only recently implemented Option B+, 
our analysis focused on treatment-eligible women who initiated cART during pregnancy in 
the pre-Option B+ era.
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Study design and population
We conducted a retrospective cohort analysis of HIV-infected pregnant women attending 
public antenatal and HIV healthcare facilities in Lusaka, Zambia. Lusaka is an urban setting 
where over 95% of women attend at least 1 ANC visit (Central Statistical Office (CSO), 
2009). Among women attending ANC, HIV testing is near universal and CD4 count 
screening coverage is approximately 80% (Chi et al., 2011). During the study period (2009–
2011), women with a CD4 count ≤350 cells/uL were eligible for lifelong cART. Data for the 
present analysis were derived from two sources: (1) the Zambian Electronic Perinatal 
Record System (ZEPRS), which collects comprehensive obstetric information on mothers 
and infants through delivery (Chi et al., 2011), and (2) SmartCare, an electronic medical 
record system for HIV clinical information.
Women included in our analysis initiated cART during pregnancy, had a CD4 count ≤350 
cells/uL (in accordance with guidelines at the time) and delivered in a public-sector facility 
between January 1, 2009 and November 2, 2010. Women were followed for up to 6 months 
after delivery. We excluded women who died during pregnancy or up to 42 days after 
delivery in order to exclude possible pregnancy-related deaths (World Health Organization, 
2015). Ethical approval for the analysis of routinely collected clinical data was obtained 
from the University of Zambia Biomedical Research Ethics Committee (Lusaka, Zambia) 
and the University of North Carolina, Chapel Hill (Chapel Hill, NC).
Outcome and predictor definitions
We followed women from delivery through 6 months postpartum. The primary endpoint was 
LTFU at 6 months postpartum. LTFU was defined as the first time a woman did not present 
to HIV care within 60 days of the last scheduled appointment. Women were categorized as 
LTFU on the 61st day after a missed appointment (Chi et al., 2010). We considered both 
clinic visits and pharmacy refill appointments. Women who never returned to HIV care after 
delivery were allowed up to 30 days to schedule an appointment and were classified as 
LTFU 61 days after that time (91 days total of follow-up time).
Three categories of predictors for LTFU at 6 months postpartum were considered: 
demographic, obstetric, and HIV characteristics. We prioritized information that would be 
readily available to clinicians at the point of care in settings like Zambia. Demographic 
predictors considered were: age, level of educational, marital status and employment status. 
Obstetric predictors considered were: number of ANC visits, parity, low infant birthweight 
(LBW; <2,500 grams) and preterm birth (<37 weeks gestation). HIV predictors considered 
were: CD4 count, WHO clinical stage, duration of cART taken during pregnancy, new 
diagnosis of HIV during pregnancy (defined as a positive HIV test within 7 days of entry 
into ANC), body mass index (BMI), hemoglobin and self-reported tuberculosis during 
pregnancy. Our aim was to develop a risk score that would be easy to calculate by frontline 
providers; as such, candidate predictors were coded as binary or categorical. Information on 
predictors of LTFU such as viral load, disclosure of HIV status to a partner and distance to 
the clinic were not available. We conducted a sensitivity analysis additionally assessing 
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enrollment into pre-ART care (e.g. enrolled but did not start treatment) prior to pregnancy as 
a candidate predictor.
Statistical analysis
The primary goal of the risk score was to create an easy to use tool for clinicians to identify 
women at delivery who may be at high risk of postpartum LTFU. The analysis comprised 
two steps. First, we developed a predictive model for LTFU at 6 months postpartum and 
used the beta coefficients as the basis for the risk score. We then validated the risk score by 
bootstrapping (Harrell, 2002).
To develop the risk score, we used logistic regression to estimate unadjusted odds ratios 
(ORs) for all candidate predictors. Predictors associated with LTFU at 6 months postpartum 
with a p-value ≤ 0.25 were identified and included in the full multivariable model. We used 
manual backward elimination based on likelihood ratio tests to reduce the full model to a 
more parsimonious final model. After the elimination of each variable, the area under the 
curve (AUC) was compared with the full model to determine whether the two models had 
comparable predictive ability. Multi-collinearity was assessed using Spearman correlations. 
For collinear variables, the variable with the strongest predictive power (e.g. largest 
coefficient) was retained in the final model. Variable elimination stopped when all predictors 
left in the multivariable model had a p-value ≤ 0.10, to balance retaining potentially 
important predictors with parsimony. Model fit was assessed using the Hosmer-Lemeshow 
test. A priori we specified a risk score cut-point with sensitivity > 80% and specificity >60% 
as optimal. These sensitivity and specificity values were selected to prioritize identifying the 
women most likely to be LTFU (higher sensitivity), while maintaining a reasonable ability to 
identify women most likely not to be LTFU.
To calculate the final risk score, beta coefficients from the final logistic regression model 
were multiplied by 10 and rounded to the nearest integer. Values for each person were 
summed to create an individual risk score. Sensitivity and specificity was assessed at each 
risk score cut-point. Risk score validation was carried out by bootstrapping the original data 
set (n=1,000) and comparing the mean, 2.5th and 97.5th percentile values for sensitivity and 
specificity to their respective values and 95% confidence intervals in the original 
data(Harrell, 2002). Statistical analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, North Carolina).
RESULTS
Of 4,305 identified in ZEPRS who started cART during pregnancy, 2,982 (69%) could be 
linked to their SmartCare records. Demographic and obstetric characteristics were similar 
between women who could be linked, and those who could not. Of the 2,982 women with 
linked records, 925 (31%) were excluded for reasons shown in Figure 1. An additional 759 
women were identified in SmartCare who initiated cART while pregnant (according to their 
ZEPRS record). A total of 2,265 women initiated cART during pregnancy within the study 
period; 2,108 (93%) had a CD4 count ≤350 and 2,034 (96%) had delivery information. Five 
women (0.2%) died within 42 days of delivery and were not included, for a final sample size 
of 2,029 women (Figure 1).
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A total of 507 (25%) women were lost to follow-up (LTFU) by 6 months postpartum; 10 
(0.5%) of whom died from non-pregnancy related causes after being LTFU. Of the 507 
women who were LTFU, 285 (56%) never returned to care after delivery. Among those who 
initially returned to care but were later LTFU, over half were lost by 18 weeks postpartum 
(Figure 2).
Overall, most women were >25 years of age (66%), married or cohabitating (93%), either 
unemployed or a housewife (74%) and attended only 1 or 2 ANC visits (65%) (Table 1). 
Most women received a HIV diagnosis (87%) during the current pregnancy. Women were 
overwhelmingly WHO clinical stage 1 or 2 (93%) and received ≥4 weeks of cART during 
pregnancy (80%).
Model development
In bivariable analyses, age, education, employment status, WHO clinical stage, duration of 
cART during pregnancy, hemoglobin, number of ANC visits, parity and preterm delivery 
predicted LTFU at 6 months postpartum (all, P < 0.25; Table 2). In the sensitivity analysis, 
having enrolled in pre-ART care prior to initiating treatment during pregnancy was a strong 
predictor of LTFU at 6 months postpartum (unadjusted OR 2.08 95% CI (1.11, 3.88)), but 
very few women (2%) were enrolled in pre-ART care.
In the multivariable analysis, parity, education, employment status, WHO clinical stage, 
duration of cART during pregnancy, and number of ANC visits predicted LTFU at 6 months 
postpartum (all P < 0.10; Table 2). The strongest predictors of LTFU were primiparity, WHO 
clinical stage 1 or 2, and receiving only 1 to 4 weeks of cART before delivery (Table 2). 
Overall, discrimination in both the full (included all predictors identified in the bivariable 
analysis) and final (excluded age, hemoglobin, and preterm delivery) models was marginal 
(full model AUC 0.64; final model AUC 0.63).
Risk score performance
The risk score ranged from 3 to a maximum score of 26 (Table 2). In the bootstrapped data, 
mean sensitivity and specificity values were consistent with sensitivity and specificity values 
in the observed data, as was 95% CI coverage, indicating good internal validity of the risk 
score.
No risk score cut-point met our a priori targets for acceptable performance (sensitivity 
>80%, specificity >60%). Overall, sensitivity was approximately ≥80% for risk score cut-
points below 12, indicating a reasonably good ability to accurately identify women who 
became LTFU. Specificity for the same range of risk scores was low (0–22%). For example, 
selecting a risk score cut-point of 11 resulted in 85% sensitivity (95% CI 0.82, 0.88) and 
22% specificity (95% CI 0.20, 0.24) to detect women LTFU by 6 months postpartum (Figure 
3a). With a 25% prevalence of LTFU in our population, the positive predictive value (PPV) 
for a cut-point of 11 was 0.27 (95% CI 0.24, 0.29) and the negative predictive value (NPV) 
was 0.81 (95% CI 0.78, 0.85; Figure 3b). Using a risk score cut-point of 11 would identify a 
large group of women for intervention and exclude only 411 (20%) of the 2,029 women in 
our study population from a retention intervention.
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Alternatively, a risk score cut-point with lower sensitivity and higher specificity could be 
used to target a smaller group of women with higher likelihood of LTFU for an intensive 
retention intervention. A risk score cut-off of 18 identified the 23% of women (n=460) with 
the highest probability of LTFU and had sensitivity 0.32 (95% CI 0.28, 0.36) and specificity 
0.80 (95% CI 0.78, 0.82). PPV improved slightly to 0.35 (95% CI 0.31, 0.40) and NPV) was 
0.78 (95% CI 0.76, 0.80. Estimates of sensitivity and specificity for each risk score cut-point 
changed minimally when enrollment in pre-ART care was included as a predictor.
DISCUSSION
We developed a simple and easy to use risk score to identify women initiating cART during 
pregnancy with a high likelihood of LTFU by 6 months postpartum. No risk score cut-point 
met our a priori criteria for a satisfactory combination of sensitivity and specificity 
(sensitivity >80% and specificity >60%). PPV was also low, but will vary with the 
underlying prevalence of LTFU in the population (Figure 3). However, the risk score may 
still be useful to target a subgroup of women at delivery for retention interventions.
In our study population, a risk score cut-off of 11 identified 80% of our study population for 
intervention and could be used to identify a larger group of women at moderate risk of LTFU 
for a low-intensity intervention. Alternatively, a cut-point of 18 identified the 23% of our 
study population with the highest likelihood of LTFU and may be more appropriate for 
targeting a smaller group with a high-intensity intervention.
Our risk score is intended for use in maternity care settings in SSA, where the characteristics 
of women initiating cART during pregnancy and postpartum LTFU are likely to be similar to 
our study population. Prior to discharging women after delivery, practitioners could 
complete a simple checklist to assess likelihood of being LTFU (see example in Appendix). 
The risk score could then be used to either identify women less likely to become LTFU, so 
that resources are appropriately directed to those at greater risk. Alternatively, the tool could 
be used to identify those women at highest risk of LTFU, an approach which may be more 
practical in settings with limited funds for retention interventions. If adequate funds are 
available, it may be preferable to enroll all women in retention interventions. As with all risk 
scores, validation of our risk score prior to implementation is essential. If women initiating 
cART in our study population differ from women initiating cART in other settings, the 
predictive ability of the risk score may differ.
We designed our risk score to be used after delivery, in order to maximize the information 
available to clinicians. However, many of the factors determined at delivery (e.g. low 
birthweight) were not included in the final risk score, raising the possibility that ANC may 
be a preferable time to identify women at high risk of LTFU. Identifying women primary 
care setting may be more effective since it facilitates earlier intervention for women likely to 
become LTFU and programmatically more efficient since women may return to the same 
care clinic later to receive HIV treatment. Additional work is needed to explore whether the 
information available to clinicians during ANC is sufficient to develop a satisfactory risk 
score.
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Predicting postpartum LTFU is difficult. In our analysis, we used data likely to be available 
to clinicians at the time of delivery. However, none of the characteristics strongly predicted 
LTFU at 6 months postpartum. To improve the predictive ability of the risk score, 
information on additional predictors may be necessary. Clinicians could consider asking 
women at delivery about whether they have disclosed their HIV status to their partner 
(Halperin, Pathmanathan, & Richey, 2013; Wohl et al., 2011), face structural barriers to 
seeking care such as transportation or financial burdens (Bogart et al., 2012; Higa, Marks, 
Crepaz, Liau, & Lyles, 2012) or have concerns about stigma (Bogart et al., 2012; Kempf et 
al., 2010). Each of these factors has been shown to predict LTFU, but such information is 
rarely collected as part of routine care. Further research is needed to determine whether 
information on social and structural barriers to care is sufficient to produce a risk score with 
satisfactory sensitivity and specificity.
Many of the predictors identified in our analysis have previously been associated with 
LTFU. We found that a lower level of education and being a housewife or unemployed 
predicted LTFU. Higher education, which may influence employment status, has been 
shown to improve cART adherence, as well as retention in care (Ayuo et al., 2013; 
Bardeguez et al., 2008; Panditrao et al., 2011). We also found that fewer ANC visits and 
shorter duration of cART during pregnancy predicted LTFU, which aligns with previous 
findings that late presentation to ANC is associated with postpartum LTFU (Panditrao et al., 
2011). We were unable to assess whether initiating treatment with a CD4 count >350 
cells/uL predicted LTFU, because of existent thresholds for CD4 eligibility during the study 
period. However, as Option B+ is scaled up, the need for CD4 count monitoring may 
become obsolete, since women will initiate treatment regardless of CD4 count. In our 
analysis, WHO stage 1 or 2 was associated with LTFU, suggesting that women who are 
otherwise asymptomatic and healthy (ie. CD4 >350 cells/uL) may be at an increased risk of 
LTFU (Clouse et al., 2013; Tenthani et al., 2014). As seen in other studies (Boyles et al., 
2011), enrollment in pre-ART care prior to pregnancy strongly predicted LTFU; however 
very few women met this definition.
There was substantial LTFU in our cohort. Of the 2,029 women included in the study 
population, 25% (n=507) were LTFU by 6 months postpartum. In our study we followed 
women from delivery, rather than cART initiation, to assess LTFU after engagement with the 
healthcare system during pregnancy. In countries that have implemented Option B+ similar 
trends have been seen, with 12–24% of women reported LTFU or to have no follow-up by 6 
months after cART initiation (Kieffer et al., 2014; Tenthani et al., 2014). Among women 
LTFU in our study, 56% (n=285) did not return to care after delivery. The high proportion of 
LTFU immediately following delivery has also been reported in South Africa, where among 
women who initiated cART during pregnancy, 64% of women LTFU never returned to care 
after delivery(Clouse et al., 2013). In Malawi, women who started cART while pregnant 
were five times as likely to never return to care, compared to non-pregnant patients initiating 
cART for their own health (Tenthani et al., 2014).
Improving retention in care is critical to the success of scaling up lifetime cART to pregnant 
and breastfeeding women (Ahmed et al., 2013; Schouten et al., 2011). Women initiating 
treatment during pregnancy face the dual stresses of maintaining engagement in HIV care 
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and having a new infant to care for, making them particularly vulnerable to LTFU (Hodgson 
et al., 2014; Kaplan et al., 2008). In our population, over half of the women who were LTFU 
never returned to HIV care after delivery. It is possible that some of these women migrated 
from Lusaka after delivery and later returned to care. However the high proportion of 
women lost immediately after delivery suggests that interventions to improve postpartum 
retention in care may need to engage with women before delivery and focus on keeping 
women in care immediately following birth.
CONCLUSIONS
Maintaining engagement in care for HIV-infected women initiating cART is essential for 
PMTCT and improving the health of HIV-infected mothers. As Option B+ is scaled up 
throughout SSA, healthcare systems must balance the additional costs of providing lifelong 
treatment to pregnant and breastfeeding women with prevention efforts to reduce LTFU 
(Ciaranello et al., 2013; Kuznik et al., 2012). Risk scores offer a simple and easy tool that 
can be employed at delivery, when women are still engaged in care, to identify women most 
likely to benefit from an intervention to reduce LTFU. However, accurately predicting LTFU 
among postpartum women is difficult and supplementary information, including data from 
women initiating treatment under Option B+, may be needed to maximize risk score 
effectiveness.
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Appendix
Risk Score for Loss to Follow-up by 6 months Postpartum
Directions:
• All women start with a score of 0.
• Check off box correct category for each risk factor.
• Sum the points for all risk factors and record the final risk score at the 
bottom.
Risk Factor Check correct box Points
Education level
  Secondary or tertiary ▭ 0
  Primary or none ▭ 3
Employment status
  Employed or student ▭ 0
  Housewife or unemployed ▭ 4
WHO clinical stage (at entry into ANC)
  3 or 4 ▭ 0
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Risk Factor Check correct box Points
  1 or 2 ▭ 5
Duration of cART before delivery (current pregnancy)
  <4 weeks ▭ 0
  1–4 weeks ▭ 5
Number of ANC visits (current pregnancy)
  >3 ▭ 0
  1 or 2 ▭ 3
Parity (number of previous deliveries)
  >2 ▭ 0
  2 ▭ 3
  1 ▭ 3
  0 ▭ 6
Sum points for all checked boxes
RISK SCORE ▭
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Inclusion criteria for 2, 029 HIV-infected pregnant women who initiated cART during 
pregnancy and had linkable records, included in the study population. ZEPRS=Zambian 
Electronic Perinatal Record System; SmartCare = HIV electronic medical record system.
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Timing of loss to follow-up among 222 women returned to HIV care after delivery and who 
were subsequently lost to follow-up. An additional 285 women (507 women LTFU in total) 
never returned to HIV care after delivery and are not included.
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A. Sensitivity (solid line) and specificity (dotted line) at each risk score cut-off (range 3–26) 
to predict LTFU at 6-months postpartum among 2,029 HIV-infected Zambian women who 
initiated cART during pregnancy. B. Positive predictive value (PPV; dashed line) and 
negative predictive value (NPV; solid line) for risk score cut-point 11, as the prevalence of 
LTFU varies.
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Table 1














  ≤ 25 201 (39.6) 483 (31.8) 684 (33.7)
  >25 306 (60.4) 1,037 (68.2) 1,343 (66.3)
Level of education
  None or primary 211 (48.0) 540 (40.4) 751 (42.2)
  Secondary or tertiary 229 (52.1) 798 (59.6) 1,027 (57.8)
Marital status
  Married or cohabitating 450 (91.7) 1,353 (91.6) 1,804 (92.6)
  Singled, divorced or
widowed 41 (8.4) 125 (8.5) 166 (8.4)
Employment status
  Employed or student 85 (19.1) 380 (28.1) 465 (25.8)
  Housewife or unemployed 361 (80.9) 974 (71.9) 1,335 (74.2)
CD4 count (cells/uL)
  ≤150 118 (23.5) 377 (25.1) 495 (24.7)
  151–250 202 (40.2) 557 (37.1) 759 (37.9)
  251–350 118 (36.3) 566 (37.7) 748 (37.4)
WHO stage
  1 or 2 458 (92.9) 1,360 (91.1) 1,818 (92.5)
  3 or 4 35 (7.1) 133 (8.9) 168 (8.5)
Duration of antenatal cART
  1–4 weeks 18 (27.2) 274 (18.0) 412 (20.3)
  > 4 weeks 369 (72.8) 1,248 (82.0) 1,617 (79.7)
New HIV diagnosis during
pregnancy
  Yes 439 (86.6) 1,328 (87.3) 1,767 (87.1)
  No 68 (13.4) 194 (12.8) 262 (12.9)
Body mass index (kg/m2)
  <18.5 15 (3.2) 46 (3.2) 61 (3.2)
  18.5 –<25 306 (64.7) 923 (63.4) 1,229 (63.7)
  25 – <30 125 (26.4) 392 (26.9) 517 (26.8)
  ≥30 27 (5.7) 96 (6.6) 123 (6.4)
Hemoglobin (g/dL)
  <8 17 (3.7) 45 (3.2) 62 (3.4)
  8–<10 105 (22.9) 357 (25.7) 462 (25.0)
  ≥ 10 337 (73.4) 990 (71.1) 1,327 (71.7)
Active tuberculosis

























  Yes 10 (2.0) 23 (1.5) 33 (1.6)
  No 497 (98.0) 1,499 (98.5) 1,996 (98.4)
Number of ANC visit
  1 or 2 358 (70.6) 966 (63.5) 1,324 (65.3)
  ≥3 149 (29.4) 556 (36.5) 704 (34.8)
Parity
  0 108 (22.0) 252 (17.2) 360 (18.4)
  1 126 (25.7) 358 (24.4) 484 (24.7)
  2 112 (5.7) 343 (23.4) 455 (23.3)
  >2 144 (29.4) 515 (35.1) 659 (33.7)
Low birthweight (<2,500 grams)
  Yes 82 (16.5) 204 (13.7) 286 (14.4)
  No 414 (83.5) 1287 (86.3) 1,701 (85.6)
Preterm delivery (<37 weeks
gestation)
  Yes 179 (41.2) 461 (35.6) 640 (37.0)
  No 256 (58.9) 835 (64.4) 1,091 (63.0)
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Table 2
Predictors of loss to follow-up from HIV care at 6 months postpartum among HIV-infected Zambian women 
initiating cART during pregnancy.
Unadjusted Full Model Final Model
Risk Score
Covariate OR (95% CI) OR (95% CI) OR (95% CI)
Age
  >25 1.00 1.00
  ≤ 25 1.41 (1.15, 1.74)a 1.10 (0.77, 1.56)
Education
  Secondary or tertiary 1.00 1.00 1.00 --
  Primary or none 1.36 (1.10, 1.69)a 1.33 (1.01, 1.76) 1.41 (1.10, 1.80)b 3
Marital status
  Married or cohabitating 1.00 --
  Singled, divorced or widowed 1.18 (0.86, 1.62) --
Employment status
  Employed or student 1.00 1.00 1.00 --
  Housewife or unemployed 1.66 (1.27, 2.16)a 1.47 (1.06, 2.03) 1.56 (1.17, 2.07)b 4
CD4 count (cells/uL)
  251–350 1.00 --
  151–250 1.13 (0.89, 1.42) --
  ≤150 0.97 (0.75, 1.27) --
WHO Clinical Stage
  3 or 4 1.00 1.00 1.00 --
  1 or 2 1.28 (0.87, 1.89)a 2.18 (1.26, 3.75) 1.73 (1.10, 2.73)b 5
Duration of cART before delivery
  > 4 1.00 1.00 1.00 --
  1–4 1.70 (1.35, 2.16)a 1.69 (1.23, 2.32) 1.73 (1.32, 2.27)b 5
HIV diagnosis during pregnancy
  No 1.00 --
  Yes 0.94 (0.70, 1.27) --
Body mass index (kg/m2)
  18.5 – <25 1.00 --
  <18.5 0.98 (0.54, 1.79) --
  25 – <30 0.96 (0.76, 1.22) --
  ≥30 0.85 (0.54, 1.33) --
Hemoglobin (g/dL)
  ≥10 1.00 1.00
  8–<10 0.86 (0.67, 1.11)a 0.86 (0.63, 1.18)
  <8 1.11 (0.63, 1.97) 1.83 (0.87, 3.83)
Active tuberculosis
  No 1.00 --
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Unadjusted Full Model Final Model
Risk Score
Covariate OR (95% CI) OR (95% CI) OR (95% CI)
  Yes 1.31 (0.62, 2.77) --
Number of ANC visits
  ≥ 3 1.00 1.00 1.00 --
  1 or 2 1.38 (1.11, 1.72)a 1.31 (0.97, 1.76) 1.31 (1.02, 1.68)b 3
Parity
  >2 1.00 1.00 --
  2 1.17 (0.88, 1.55) 1.09 (0.76, 1.57) 1.31 (0.96, 1.81)b 3
  1 1.26 (0.96, 1.66)a 1.19 (0.80, 1.76) 1.42 (1.04, 1.94)b 3
  0 1.53 (1.15, 2.05)a 1.30 (0.80, 2.10) 1.83 (1.29, 2.59)b 6
Low birthweight (<2,500 grams)
  No 1.00 --
  Yes 1.25 (0.95, 1.65) --
Preterm delivery (<37 weeks gestation)
  No 1.00 1.00
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